|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
Having doubled its market share in 2011 when compared to 2005, the global pediatric vaccine market has been forecast to increase at a single digit compound annual growth rate (CAGR) through to 2015, to reach a market value of more than US$23 billion.
This incremental growth has been due to blockbuster vaccines (Prevnar7, Prevnar 13, Rotarix and Rotateq) sales in billions of US$ which made a significant contribution.
Despite ongoing improvements in pediatric vaccination, it is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. This problem is most significant in low income countries, with the health disparity between rich and poor countries resulting in average life spans of about 77 and 52 years, respectively.
In addition to this high death toll, millions more suffer disability and illness because they have not been immunised. Adult immunisation is an important, but frequently overlooked, part of patient care. Vaccination programs typically focus on children, yet adults in industrialised countries are more likely to die as a result of vaccine-preventable diseases than are children.
Vaccines are available for 20 different infectious diseases, and vaccines against 10 deadly diseases are recommended for use in all US children. Vaccines not only protect the child that receives them, but just as important, they protect the health of the community in which the child lives.
Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly.
Those who did not receive measles vaccine due to philosophical or religious reasons were 35 times more likely to contract measles, and could potentially increase the incidence of measles in their community by as much as 30%.
The worldwide pediatric vaccine market is dominated by five major competitors: Merck & Co, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. These companies have made earning a greater share of the vaccine market part of their marketing and research strategies. GlaxoSmithKline is in the lead with nearly a quarter of the global market, largely due to its influenza products Fluvarix and Hiberix.
For more information on the global pediatric vaccine market, see the latest research: Global Pediatric Vaccine Market
Follow us on Twitter @CandMResearch
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.
Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.
We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.